Drug intelligence / Profile preview

F2C22C

Development stage: Unknown
Lead developer: GSK
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

F2C22C is referenced as a test article in early phase vaccine research sponsored by GlaxoSmithKline, specifically mentioned in the context of a protocol for a clinical study investigating a messenger RNA vaccine. As of the latest information available, F2C22C appears to be a **candidate experimental product or internal code** for a vaccine or vaccine component evaluated for immunogenicity and safety, but no public evidence indicates a defined molecular structure, mechanism of action, or clinical development beyond early studies[4].

Beyond the preview

Go deeper on F2C22C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F2C22C.

Explore the full profile